Compare Amphastar Pharmaceuticals Inc (AMPH) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Hilton Hotels Corporation Common Stock — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Hilton Hotels Corporation Common Stock trades at $316 (market cap $70.00B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 81× Amphastar Pharmaceuticals Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | HLT | |
|---|---|---|
Market Cap | $863.95M | $70.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $350.22 |
52-Week Low | $16.87 | $256.75 |
Enterprise Value | $1.26B | $83.01B |
Dividend Yield | — | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Hilton Worldwide (HLT) trades at $317.60, down 1.36% with bearish technical signals. The stock shows strong fundamentals with consistent earnings beats and revenue growth from $12.04B in 2025 to projected $12.5B in 2026. Analyst consensus remains positive with 57% buy ratings and a $352.88 price target, though technical indicators show selling pressure near key resistance at $321.
HLT offers growth potential from travel recovery and pipeline expansion but faces risks from premium valuation (P/E 46.64), rising debt levels (debt-to-asset ratio increased to 73.88% in 2025), and labor disputes. The stock's near-term performance depends on Q3 earnings meeting expectations of $2.38 EPS and managing global demand volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
